

Product Name: Apremilast (CC-10004) Revision Date: 01/10/2021

Product Data Sheet

Apremilast (CC-10004)

Cat. No.: A4317

608141-41-9 CAS No.: Formula: C22H24N2O7S


M.Wt: 460.5

Synonyms:

Target: Metabolism

PDE Pathway:

Storage: Store at -20°C



Solvent & Solubility

≥23.05 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH

In Vitro

Preparing Stock Solutions	Solvent Concentration	1mg	5mg	10mg
	1 mM	2.1716 mL	10.8578 mL	21.7155 mL
	5 mM	0.4343 mL	2.1716 mL	4.3431 mL
	10 mM	0.2172 mL	1.0858 mL	2.1716 mL

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

PDE4 inhibitor			
74 nM (PDE4)			
Cell Viability Assay			
Cell Line:	U937 human monocytic cells		
Preparation method: The solubility of this compound in DMSO is >10 mM. General tips for obtain			
	a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or		
	shake it in the ultrasonic bath for a while. Stock solution can be stored below		
	-20°C for several months.		
Reacting conditions:	18h; IC50=74 nM		
	74 nM (PDE4) Cell Viability Assay Cell Line: Preparation method:		

	Applications:	Apremilast was initially screened for PDE4 inhibition using a partially purified		
		enzyme preparation from U937 human monocytic cells and which has been		
		shown previously to contain predominantly PDE4B and PDE4D activities.		
		Apremilast was also found to exhibit an IC50 of around 74 nM using 1 mM		
		cAMP as substrate.		
	Animal experiment	210		
In Vivo	Animal models:	SCID mice		
	Dosage form:	5 mg·kg-1·day-1 ; oral taken		
	Applications:	The pharmacological activity of apremilast (5 mg·kg-1·day-1 total divided into 2		
		daily doses) was tested in comparison with cyclosporine (5 mg·kg-1·day-1 total		
		divided into 2 daily doses) and vehicle control (0.1 mL·day-1 divided into twice		
		daily doses) in a mouse xenograft model of psoriasis. Epidermal thickness and		
		proliferation index correlated with histological findings and demonstrated		
		significant differences between treatment groups. Notably, apremilast caused		
	810	statistically significant reductions in epidermal thickness (P < 0.001) and		
	OE Jacob	proliferation index (P < 0.001).		
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may		
		slightly differ with the theoretical value. This is caused by an experimental		
		system error and it is normal.		

Product Citations

See more customer validations on www.apexbt.com.

References

[1] Schafer P H, Parton A, Gandhi A K, et al. Apremilast, a cAMP phosphodiesterase - 4 inhibitor, demonstrates anti - inflammatory activity in vitro and in a model of psoriasis[J]. British journal of pharmacology, 2010, 159(4): 842-855.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com



APE BIO

APE BIO

APE BIO

APE BIO

APE BIO

APEVEIO.